1,4,4-三甲基-2,3-二氢喹啉 | 106515-74-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,4,4-三甲基-2,3-二氢喹啉
• 英文名称: 1,4,4-Trimethyl-1,2,3,4-tetrahydroquinoline
• 英文别名: 1,4,4-trimethyl-2,3-dihydroquinoline
• CAS: 106515-74-6
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: XYITUOIAVHTHHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,4,4-三甲基-2,3-二氢喹啉 在 sulfur 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 piperidin-1-yl(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-6-yl)methanethione
  参考文献：
  名称：

  Thiorhodamines containing amide and thioamide functionality as inhibitors of the ATP-binding cassette drug transporter P-glycoprotein (ABCB1)

  摘要：

  Twelve thiorhodamine derivatives have been examined for their ability to stimulate the ATPase activity of purified human P-glycoprotein (P-gp)-His(10), to promote uptake of calcein AM and vinblastine into multidrug-resistant, P-gp-overexpressing MDCKII-MDR1 cells, and for their rates of transport in monolayers of multidrug-resistant, P-gp-overexpressing MDCKII-MDR1 cells. The thiorhodamine derivatives have structural diversity from amide and thioamide functionality (N,N-diethyl and N-piperidyl) at the 5-position of a 2-thienyl substituent on the thiorhodamine core and from diversity at the 3-amino substituent with N, N-dimethylamino, fused azadecalin (julolidyl), and fused N-methylcyclohexylamine (half-julolidyl) substituents. The julolidyl and half-julolidyl derivatives were more effective inhibitors of P-gp than the dimethylamino analogues. Amide-containing derivatives were transported much more rapidly than thioamide-containing derivatives. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.05.075
• 作为产物：
  描述：

  N-(3-methylbut-2-enyl)-N-methylaniline 在 polyphosphoric acid 作用下， 反应 18.0h， 以83%的产率得到1,4,4-三甲基-2,3-二氢喹啉
  参考文献：
  名称：

  [EN] FLUORESCENT SYNTHETIC RETINOIDS
  [FR] RÉTINOÏDES SYNTHÉTIQUES FLUORESCENTS

  摘要：

  公开号：

  WO2016055800A3

文献信息

• Novel Heterocyclidene Acetamide Derivative
  申请人：Uchida Hideharu

  公开号：US20080287428A1

  公开（公告）日：2008-11-20

  A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R 1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO 2 group, or the like; R 2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X 1 represents O, —NR 3 —, or —S(O)r-; X 2 represents a methylene group, O, —NR 3 —, or —S(O)r-; Q′ represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.

  一个由式(I′)表示的化合物：（其中m、n和p分别表示0到2；q表示0或1；R1表示卤素、烃基、杂环基、烷氧基、烷氧羰基、磺酰胺基、CN基团、NO2基团等；R2表示卤素、氨基、烃基、芳香杂环基或醛基；X1表示O、—NR3—或—S(O)r-；X2表示亚甲基、O、—NR3—或—S(O)r-；Q′表示异芳基基团、异芳基烷基基团、取代芳基基团或芳基烷基基团；Cycle moiety代表芳基环或杂芳基环；波浪线表示E异构体或Z异构体），该化合物的盐，或该化合物或其盐的溶剂络合物。一种药物组合物和一种瞬时受体电位类型I（TRPV1）受体拮抗剂，每种包含至少一种该化合物、该化合物的盐，或该化合物或其盐的溶剂络合物作为活性成分。
• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110195954A1

  公开（公告）日：2011-08-11

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

  本发明涉及一般式I的新CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所述定义，其互变异构体、异构体、顺反异构体、对映异构体、水合物、混合物及其盐，以及其盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，包含这些化合物的药物、其用途以及其制备方法。
• Mono-or polyenic carboxylic acid derivatives
  申请人：Eisai Co., Ltd.

  公开号：US05977125A1

  公开（公告）日：1999-11-02

  Compounds of the formula ##STR1## and compounds of the formula ##STR2## or their salts have the potent ability to bind to retinoic acid receptors thus useful in treating psoriasis and rheumatoid arthritis.

  公式为##STR1##的化合物和公式为##STR2##的化合物或它们的盐具有与视黄酸受体结合的强大能力，因此在治疗牛皮癣和类风湿性关节炎方面非常有用。
• [EN] METHODS AND COMPOUNDS FOR PHOTOTHERAPY WITH CHALCOGENORHODAMINE PHOTOSENSITIZERS<br/>[FR] PROCÉDÉS ET COMPOSÉS DE PHOTOTHÉRAPIE FAISANT APPEL À DES PHOTOSENSIBILISANTS DE TYPE CHALCOGÉNORHODAMINE
  申请人：UNIV WAKE FOREST HEALTH SCIENCES

  公开号：WO2015187940A1

  公开（公告）日：2015-12-10

  A method of selectively depleting pathogenic T lymphocytes from a blood cell composition is carried out by (a) combining the cell composition ex vivo with an active compound in an effective amount, and then (b) irradiating the cells with light ex vivo for a time and at an intensity sufficient to selectively kill pathogenic T lymphocytes in said cell composition. Chalcogenorhodamine photosensitizers useful as such active compounds are also described.

  一种从血细胞组合物中选择性消耗致病性T淋巴细胞的方法是通过(a)在体外将细胞组合物与有效量的活性化合物结合，然后(b)在体外用光辐照细胞，时间和强度足以选择性地杀死该细胞组合物中的致病性T淋巴细胞。还描述了作为这种活性化合物有用的硫属罗丹明光敏剂。
• MONO- OR POLYENIC CARBOXYLIC ACID DERIVATIVE
  申请人：Eisai Co., Ltd.

  公开号：EP0790228A1

  公开（公告）日：1997-08-20

  To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof:         Z-(CR3=CR2)n-COOR1     (1-I) Compounds represented by the general formula (2-I) or physiologically acceptable salts thereof: The compounds according to the present invention exhibit extremely high ability to bind RARs and are effective for treating various kind of diseases such as abnormality in cornification and rheumatoid arthritis.

  提供与维甲酸有关的新型化合物，这些化合物可以替代用于预防和治疗多种疾病的维甲酸，并对维甲酸具有拮抗作用。 通式（1-I）代表的杂环化合物或其生理上可接受的盐类： Z-(CR3=CR2)n-COOR1 (1-I) 通式 (2-I) 所代表的化合物或其生理学上可接受的盐： 本发明的化合物具有极高的结合 RARs 的能力，可有效治疗各种疾病，如玉米粒化异常和类风湿性关节炎。